Objectives: Acromegaly is frequently associated with thyroid diseases. In this study, we evaluated the frequency of thyroid disorders in a series of acromegalic patients. Subjects and methods:
INTRODUCTION
A cromegaly is an uncommon disease that is usual ly caused by a growth hormone (GH)secreting pituitary adenoma (1) , and is associated with a 1.7fold increase in mortality (2) . The major causes of death in clude cardiovascular, cerebrovascular, and respiratory disease (38) . Several studies have indicated that acro megalic patients also have an increased risk of develo ping both benign and malignant tumors (911).
It is wellestablished that acromegaly is associa ted with an increased prevalence of goiter (1219). Thyroid follicular cells express IGFI receptors (21) , and the continuous exposure of thyroid cells to the chronic effect of high IGFI levels may be involved in goiter development. Several authors found a positive relationship between thyroid volume and high serum levels of IGFI (1220). Several studies have found an increased prevalence of nodular goiter and thyroid car cinoma (14, 16, 1820, 22, 23) in acromegalic patients. A Brazilian study of 34 consecutive patients with acro megaly recently demonstrated that 67% of the patients had thyroid nodules and 11% had differentiated thyroid carcinoma (24) . In this study, we evaluated the fre quency of thyroid disorders in a series of acromegalic patients and correlated the occurrence of thyroid disor ders with disease activity.
METHODS Patients
The study group consisted of 106 patients with acro megaly recruited from the outpatient endocrinology clinic of the Hospital Universitário Clementino Fraga Filho (HUCFF) of the Universidade Federal do Rio de Janeiro (UFRJ) over a 12month period. Reasons for ineligibility were pregnancy, thyroid nodular diseases diagnosed before acromegaly, and patients previously submitted to total thyroidectomy. All subjects entered the study after written informed consent was signed, according to a protocol approved by the Ethics Com mittee of the HUCFF.
Laboratory diagnosis of acromegaly
Acromegaly diagnosis was based on the following crite ria: 1) a lack of suppression of GH to below 1 ng/mL after the oral administration of 75 g glucose; and 2) high levels of serum IGFI.
Clinical parameters
After documentation of age, sex, estimated acromegaly duration (determined from the time of the onset of signs and symptoms to the time of inclusion in the stu dy), and an inquiry concerning the signs and symptoms of thyroid disorders, all patients underwent clinical exa mination of the thyroid gland by the same physician (H.B.M.P.U.). All serum samples were collected early in the mor ning, after an eighthour fasting period.
Hormone assays

Thyroid ultrasound
Thyroid ultrasonography was performed by the same practitioner (S.A.C.) using a HDI 5000, ATL (Advan ced Technology Laboratories, Bothell, WA), Phillips, 2003, with a 712 MHz transducer. Thyroid volume was calculated by the elliptical shape volume formula (π/6 x length x width x thickness). Total volume was determined by the sum of each lobe and isthmus. Goi ter was defined as thyroid volume exceeding 12.6 cm 3 for women, and 17.1 cm 3 for men (26) . Morphology was classified in four categories: nor mal gland, unspecific morphological abnormalities (colloid cyst or heterogeneous texture) and diffuse and nodular goiter (uni or multinodular).
Fine-needle aspiration biopsy (FNAB)
FNAB was performed on all thyroid nodules with a diameter greater than one centimeter, or on nodules that displayed two or more suspicious characteristics in the ultrasound. All FNABs were performed by the same practitioner (S.A.C.), and were guided by ultrasono graphy. The cytopathological analysis was performed by the same pathologist (A.P.A.V.), and the results were classified according to the Bethesda system (27) .
When the patients were submitted to thyroidec tomy, all specimens were reviewed by the same patholo gist (A.P.A.V.). Thyroid cancer was staged using TNM classification (tumor, lymph node, and distant metasta sis) (28) . median (minimummaximum). Comparisons between categorical variables were performed using Fisher's exact test. Comparisons between numerical variables were performed using the MannWhitney test. Corre lations were determined by calculating Spearman's rank correlation coefficient. P values < 0.05 were considered statistically significant.
RESULTS
Study population
The main characteristics of the study population are described in table 1.
Thyroid diseases in acromegaly Data are shown as medians (minimum-maximum). * Adenoma > 10 mm. ** Basal GH < 2.5 ng/mL and normal IGF-I.
Thyroid abnormalities
Functional and morphological thyroid evaluations were performed in all 106 patients. Nineteen patients pre sented secondary hypothyroidism, and nine patients presented primary hypothyroidism (antiTPO Ab was positive in eight of them). Of the patients with primary hypothyroidism, two had subclinical hypothyroidism and were not being treated. Two patients had history of hyperthyroidism. Thyroid morphology abnormalities at ultrasound were observed in 75 patients (71.0%). Eleven patients (10.4%) had diffuse goiter, 42 (40.0%) had nodular goiter, and 22 patients (20.6%) had unspecific mor phology abnormalities (colloid cyst or heterogeneous texture). The two patients with TSH levels above the reference value presented subclinical hypothyroidism and unspecific morphology abnormalities.
Fineneedle aspiration biopsy was performed in 22 patients, and the other 20 patients did not meet the cri teria for FNAB. The Bethesda system of classification showed one unsatisfactory result (Bethesda I); 10 benign (Bethesda II); three follicular lesions of undetermined significance (Bethesda III); four follicular neoplasms (Be thesda IV); one suspicious for malignancy (Bethesda V); and three malignant lesions (Bethesda VI). Among the patients with follicular lesions, three patients underwent thyroidectomy: two had nodular hyperplasia, one had papillary carcinoma, and five were not submitted to sur gery (two refused it, and three are in a waiting list).
Considering the five patients that were not opera ted on, three of them presented Bethesda III lesions, and two presented Bethesda IV lesions. Morphological thyroid evaluation is described in table 2. Four patients (3.8%) had thyroid carcinoma (two multifocal papilla ry carcinomas, one papillary variant of follicular carci noma, and one papillary microcarcinoma). Two of the thyroid carcinoma patients were females, with a median age of 51 years, and two of the patients had active acro megaly at the time of the thyroid carcinoma diagnosis. The clinical characteristics of the patients with thyroid carcinoma are described in table 3.
The group of patients with morphological abnorma lities (group 2, n = 75) showed a greater number of women (52 vs. 10, p = 0.001), older patients (49 vs. 45 yearsold, p = 0.033), and greater thyroid volume (12.9 vs. 9.1 cm 3 , p = 0.002) compared with the group of pa tients with a normal thyroid gland at ultrasound (group 1, n = 31). No difference was found considering the following parameters: disease control, estimated acro megaly duration, IGFI, IGFI SDscore, GH, fT4 or TSH (Table 4) . Considering only the patients with morphological abnormalities, thyroid volume was weakly correlated with IGFI levels (r = 0.255, p = 0.032) and IGFI SD score (r = 0.250, p = 0.036). There was no correlation between thyroid volume and age, estimated acromegaly duration, fT4 or TSH. Thyroid volume in this group of patients was greater in the patients with active acrome galy (13.7 vs. 8.9 cm 3 , p = 0.033). In the patients with diffuse or nodular goiter, thyroid volume was greater in patients with active acromegaly (15.30 vs. 8.50 cm 3 , p = 0.028), and was weakly correlated with GH levels (p = 0.032; r = 0.304), IGFI (p = 0.013; r = 0.347), and the IGFI SDscore (p = 0.017; r = 0.335). There was no correlation between thyroid volume and the dura tion of acromegaly. TSH levels were lower in patients with nodular disease (0.73 mU/L vs. 1.18 mU/L, p = 0.007). Five of the patients with lower TSH levels and nodular diseases (n = 6) had a pituitary macroadenoma, and all the six patients had secondary hypothyroidism with normal fT4 levels.
In the group of patients with morphological abnor malities, the patients with nodular or diffuse goiter (n = 53) had greater thyroid volume (14.7 vs. 12.9 cm 3 , p < 0.001) and longer estimated acromegaly duration than patients with unspecific morphology abnormalities (6 vs. 3 years, p = 0.019).
DISCUSSION
In this series of 106 patients with acromegaly, we found a 71% prevalence of thyroid disorders, including no dular and diffuse goiter and unspecific morphological abnormalities. The high prevalence is similar to the findings of previous studies (15, 20, 24, 29) and is sup ported by evidence that IGFIdependent, TSHinde pendent signaling is important for growth regulation of the thyroid gland in humans. In acromegaly, the high intrathyroidal IGFI levels may contribute to goiter development (21) . Two findings in our study support the role of IGFI in the development of thyroid disor ders in acromegaly: the positive correlation of IGFI levels with thyroid volume and the lower TSH levels in patients with nodular goiters. All the patients with lower TSH levels and nodular goiter had secondary hy pothyroidism and were on levothyroxine replacement, with normal fT4 levels. In a recent study, Rogozinski and cols. (24) evaluated 34 acromegalic patients and found high prevalence of nodular disorder (67%). The se patients had a longer history of acromegaly. Cheung and Boyages (12) and Miyakawa and cols. (20) descri bed an important positive correlation between IGFI levels and thyroid volume, while Kasagi and cols. (13) found decreased TSH levels in acromegalic patients with nodular goiter.
In this study, the frequency of thyroid cancer in acromegalic patients was 3.8%, which may be underes timated because three patients had not yet undergo ne surgery. This frequency is approximately 300 times higher than the one reported in the overall Brazilian population (30) , and in the majority of studies that have evaluated thyroid cancer in acromegalic patients (5, 8, 10, 15, 3133 ). Balkany and Cushing (17) and Marchisotti and cols. (34) found an approximately 3% prevalence of thyroid cancer in acromegalic patients, which is similar to our findings. Tita and cols. (14) des cribed seven cases of thyroid cancer in 125 acromega lic patients (5.6%). The use of routine ultrasonography might explain the higher frequency of thyroid cancer in acromegalic patients described in recent studies. However, dos Santos and cols. (35) demonstrated a significantly increased prevalence of thyroid cancer in acromegalic patients compared with a control group. The study by dos Santos and cols. included 124 acro megalic patients from northeast Brazil and 263 age and sexmatched control subjects. Nine acromegalic patients presented thyroid carcinoma (7.2%), and only two (0.7%) in the control group, which confirmed the higher prevalence of thyroid carcinoma in acromegaly. Rogozinski and cols. found four cases of differentia ted thyroid carcinoma among 34 acromegalic patients (11%) (24) .
In this study, the patients with diffuse or nodular goiter that presented active acromegaly had greater thyroid volume than the patients with adequately trea ted acromegaly. This finding suggests that sustained ex posure to high GH and IGFI levels has a role in goiter development in the acromegalic population.
In conclusion, this study confirms the high fre quency of benign thyroid diseases in acromegalic pa tients. The prevalence of thyroid cancer was greater than expected for the overall population, which stron gly supports the indication of routine thyroid ultraso nography in patients with acromegaly.
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